Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity

Area of Science:

• Molecular Biology
• Cancer Biology
• Protein Degradation

Background:

• Missense p53 mutants accumulate in tumors, promoting cancer progression via gain-of-function mechanisms.
• MDM2 targets wild-type p53 for degradation, but fails to degrade mutant p53 in tumor cells.
• Mutant p53 inhibits MDM2's E3 ligase activity, potentially by interfering with MDM2 autoubiquitination.

Purpose of the Study:

• To investigate the molecular mechanism by which mutant p53 inhibits MDM2 E3 ligase activity.
• To elucidate how mutant p53 binding affects MDM2's interaction with its substrates and its autoactivation mechanism.

Main Methods:

• Biochemical assays to measure binding avidity between mutant p53 and MDM2 domains.
• Analysis of ubiquitin transfer and release kinetics in the p53-MDM2 complex.
• Utilized engineered MDM2 constructs to assess the role of the acidic domain in p53 ubiquitination.

Main Results:

• Mutant p53's core domain binds the MDM2 acidic domain with higher avidity than wild-type p53.
• The mutant p53-MDM2 complex exhibits reduced efficiency in catalyzing ubiquitin release from E2 conjugating enzymes.
• An MDM2 construct with an amplified acidic domain resisted mutant p53 inhibition, promoting mutant p53 ubiquitination and degradation.

Conclusions:

• Mutant p53 inhibits MDM2 activity by disrupting its intramolecular autoactivation mechanism.
• This disruption leads to reduced ubiquitination and subsequent accumulation of mutant p53 in tumor cells.
• Targeting the mutant p53-MDM2 interaction could offer therapeutic strategies for cancers with p53 mutations.